YMRC
BEAM icon

Yorktown Management & Research Company’s Beam Therapeutics BEAM Stock Holding History

Yorktown Management & Research Company’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$774K Buy
+22,550
New +$681K 0.47% 62
2022
Q4 		– Sell
-5,005
Closed -$238K – 187
2022
Q3 		$238K Buy
+5,005
New +$286K 0.31% 155

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Yorktown Management & Research Company's BEAM Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 22,550 shares worth $774K. The stake represents 0.47% of the portfolio and ranks #62 among its holdings. This is a return to the name: Yorktown Management & Research Company previously reported a position in BEAM as recently as Q3 2022.

Yorktown Management & Research Company first reported a position in BEAM in Q3 2022 and has held it in 2 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Yorktown Management & Research Company held 22,550 shares of Beam Therapeutics worth $774K as of Q2 2026.
  • Beam Therapeutics was a new Yorktown Management & Research Company position in Q2 2026.
  • Beam Therapeutics made up 0.47% of Yorktown Management & Research Company's portfolio in Q2 2026, its #62 holding.
  • Yorktown Management & Research Company first reported a position in Beam Therapeutics in Q3 2022 and has held it in 2 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.